BioSkryb Genomics
PrivateLast Round
Series A
May 1, 2025
Total Funding Raised
$31.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BioSkryb Genomics operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series A round in May 2025.
BioSkryb Genomics is a biotechnology company that develops a genome amplification system leveraging cellular heterogeneity to provide scientists and clinicians with comprehensive insights into the genome, transcriptome, and proteome of individual cells for the study of complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSkryb Genomics Comparables
Compare BioSkryb Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mission Bio | 83% | |
| Xingeyuan Biotechnology | 79% | |
| Atrandi Biosciences | 79% |
For institutional investors. Book with your work email.
BioSkryb Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 1, 2025 | ||||
| Seed | Jan 9, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioSkryb Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Anzu Partners | Series A, Seed |
| Wilson Sonsini Goodrich & Rosati | Seed, Series A |
| Seed Healthcare | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 42% MoM, reaching 7.7K.
- Jul 28, 2026
Monthly visitors increased 37% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 19, 2026
BioSkryb Genomics, Inc. appoints William E. Evans, Pharm.D. as Chief Executive Officer in North Carolina on Aug 19th '26; he has served on its Board of Directors and as Chair of its Scientific Advisory Board since 2019 and succeeds Suresh Pisharody.
- hiresAug 19, 2026
BioSkryb Genomics, Inc. appoints William E. Evans, Pharm.D. as Chief Executive Officer in North Carolina on Aug 19th '26, succeeding Suresh Pisharody.
- promotesAug 19, 2026
In North Carolina, BioSkryb Genomics, Inc. promotes Bill Evans from Scientific Advisory Board Chair to CEO to drive the company’s business and clinical applications.
For institutional investors. Book with your work email.
BioSkryb Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioSkryb Genomics's valuation, stock price, and market status.
Is BioSkryb Genomics a public or private company?
BioSkryb Genomics is a private company.
What is the current stock price of BioSkryb Genomics?
BioSkryb Genomics is a private company, so its shares have no public market price. Caplight tracks BioSkryb Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioSkryb Genomics worth (valuation)?
Valuation information for BioSkryb Genomics is not publicly available.
Can I buy BioSkryb Genomics stock?
BioSkryb Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioSkryb Genomics's last funding round?
BioSkryb Genomics's most recent funding round was Series A on May 1, 2025.
Who are the main investors in BioSkryb Genomics?
Key investors in BioSkryb Genomics include Anzu Partners.
Will BioSkryb Genomics IPO soon?
No public IPO plans have been announced for BioSkryb Genomics.
How can I track BioSkryb Genomics secondary market activity?
Caplight tracks bids, offers, and trades in BioSkryb Genomics's shares on secondary markets.